VRDN - Viridian Therapeutics Inc (Healthcare: Biotechnology) Projected Earnings Date: 2025-08-05    (Delayed quote data   2025-07-11)
Last
 17.04		 Change
 ⇓ -0.09   (-0.53%)		 Volume
  462,708
Open
 16.93		 High
 17.39		 Low
 16.78
8EMA (Daily)
 16.25		 40EMA (Daily)
 14.95		 50EMA (Daily)
 14.84		 STO (Daily)
 89.095		 MACD Hist (Daily)
 0.466
8EMA (Weekly)
 15.183		 40EMA (Weekly)
 15.96		 50EMA (Weekly)
 16.27		 STO (Weekly)
 82.572		 MACD Hist (Weekly)
 0.912
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com